Growth Opportunity Celogics is expanding to a state-of-the-art biomanufacturing facility in Washington, signaling strong demand for iPSC-derived cell products and related services.

Strategic Partnership A newly formed joint venture between Curi Bio and NEXEL presents a collaborative entry point for co-developed cell products, technology sharing, and combined sales motion to Biotech and Pharma customers.

Product Focus Initial offering centers on research-use-only iPSC-derived cells for drug discovery, safety screening, and disease modeling, aligning with customers seeking advanced human cell models.

Market Readiness Seattle-based location and planned Mukilteo HQ provide regional access to West Coast biotech clusters, enabling quicker customer engagement, pilots, and on-site demonstrations.

Financial Signals Revenue range indicates emerging traction with potential upsell opportunities into larger-scale manufacturing and customized cell product programs as the company scales.